CN106361976A - 一种安神助眠养颜复方制剂及其制备方法 - Google Patents
一种安神助眠养颜复方制剂及其制备方法 Download PDFInfo
- Publication number
- CN106361976A CN106361976A CN201610758191.7A CN201610758191A CN106361976A CN 106361976 A CN106361976 A CN 106361976A CN 201610758191 A CN201610758191 A CN 201610758191A CN 106361976 A CN106361976 A CN 106361976A
- Authority
- CN
- China
- Prior art keywords
- compound preparation
- skin care
- parts
- mental strain
- relieving mental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 150000001875 compounds Chemical class 0.000 title claims abstract description 45
- 230000001914 calming effect Effects 0.000 title abstract description 14
- 210000005036 nerve Anatomy 0.000 title abstract description 14
- 230000001737 promoting effect Effects 0.000 title abstract description 9
- 230000003796 beauty Effects 0.000 title abstract 5
- 210000000582 semen Anatomy 0.000 claims abstract description 47
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 32
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 32
- 235000008434 ginseng Nutrition 0.000 claims abstract description 32
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 22
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 22
- 230000003340 mental effect Effects 0.000 claims description 49
- 241000208340 Araliaceae Species 0.000 claims description 31
- 238000003756 stirring Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000011812 mixed powder Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 230000007159 enucleation Effects 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 43
- 230000006870 function Effects 0.000 abstract description 4
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- 235000021018 plums Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 46
- 229940079593 drug Drugs 0.000 description 25
- 210000000952 spleen Anatomy 0.000 description 23
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 22
- 206010022437 insomnia Diseases 0.000 description 22
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 18
- 238000011282 treatment Methods 0.000 description 13
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000002936 tranquilizing effect Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 210000001835 viscera Anatomy 0.000 description 8
- 206010033557 Palpitations Diseases 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 230000000517 effect on sleep Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000010612 desalination reaction Methods 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003640 drug residue Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002557 soporific effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000003457 Shi epoxidation reaction Methods 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种安神助眠养颜复方制剂及其制备方法,该安神助眠养颜复方制剂,由如下重量份数计组分制备而成:酸枣仁5‑10份、龙眼肉2‑12份、人参3‑15份、茯苓3‑5份、莲子2‑6份、黄精1‑4份、桔梗2‑6份、苦瓜5‑20份、乌梅0.5‑3份、蜂蜜2‑4份。本发明的安神助眠养颜复方制剂具有安神助眠养颜的作用,且安全可靠,效果显著,无任何副作用。
Description
技术领域
本发明涉及中药保健领域,更具体地说,涉及一种安神助眠养颜复方制剂及其制备方法。
背景技术
人生的1/3时间是在睡眠中度过的。睡眠作为生命所必须的过程,是人的生理需要,是机体复原、整合和巩固记忆的重要环节,是健康不可缺少的组成部分。但目前我国38%的人群存在各类睡眠问题。失眠是一种明显降低生活质量,引起人体代谢变差、皮肤衰老加快、面色萎黄、色斑沉着、抑郁等疾病。如何调节好我们的睡眠,怎样科学地面对失眠,应成为公众日益关注的问题。
以往人们会采用西药助眠的方法,但实际上,西药助眠,存在一定的健康隐患,许多失眠患者在服药数轴后或者数月后,都出现了头昏脑胀、口干、心慌胸闷、出虚汗等各自副反应。不仅如此,许多患者在长时间服用安眠药后形成药物依赖,给身心带来更多困扰。
发明内容
本发明要解决的技术问题在于,针对现有技术的上述缺陷,提供一种安神助眠养颜复方制剂及其制备方法,该安神助眠养颜复方制剂采用天然、无毒害作用的植物提取物或中草药提取物,在总结验方的基础上,针对失眠的病因病机,按照中医辩证论治的组方原则,以补为主,补其五脏不足,达到扶正祛邪目的;以通为辅,通其气血滞瘀;以和为贵,调和诸药的药性;以清为佐,清脏腑热而安神。故补、通、和、清四法结合治疗多种原因引起的失眠,标本兼治,疗效显著。
本发明解决其技术问题所采用的技术方案是:提供一种安神助眠养颜复方制剂,由如下重量份数计组分制备而成:
本发明所述的安神助眠养颜复方制剂,其中,由如下重量份数计组分制备而成:
本发明所述的安神助眠养颜复方制剂,其中,由如下重量份数计组分制备而成:
本发明所述的安神助眠养颜复方制剂,其中,所述酸枣仁、人参、苦瓜的用量比例为1:(0.5-1.5):(1-2)。
本发明所述的安神助眠养颜复方制剂,其中,所述酸枣仁、人参、苦瓜的用量比例为1:0.8:1.5。
本发明所述的安神助眠养颜复方制剂,其中,所述酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅均粉碎成超细粉。
本发明所述的安神助眠养颜复方制剂,其中,所述酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅的平均粒径均在300目以上。
本发明还提供一种如上所述的安神助眠养颜复方制剂的制备方法,包括如下步骤:
(1)按配方量称取各个组分;
(2)乌梅去核留肉,将酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅烘干后,分别粉碎至超细粉,然后混合均匀,得到混合粉体;
(3)加入适量纯净水和蜂蜜的混合溶液,用搅拌桨缓慢匀速搅拌,搅拌40-45min后成桨料,向浆料内少量多次加入混合粉体,继续搅拌,直至混合均匀。
本发明所述的安神助眠养颜复方制剂的制备方法,其中,所述步骤(2)中,各药材粉末平均粒径均在300目以上。
实施本发明的安神助眠养颜复方制剂及其制备方法,具有以下有益效果:
(1)本发明的安神助眠养颜复方制剂具有安神助眠、养颜的作用,且安全可靠,效果显著,无任何副作用。本发明的安神助眠养颜复方制剂中,酸枣仁取其主治虚烦不眠,惊悸多梦之证,龙眼肉取其补益心脾,养血安神之功,人参取其滋补脾益肺、生津止渴、安神益智之功效,三药合用,作为君药,具有益气补血、宁心安神之功效。而茯苓取其益脾和胃、宁心安神的功效,莲子取其养生安神、补脾益肾的功效,黄精取其健脾、补肾、润肺的功效;三药合用,作为臣药,具有进一步辅助加强君药的宁心安神之功。而桔梗取其宣肺、排脓的功效,苦瓜取其清肝泻火的功效,来辅助治疗肝火上升型症状心悸而烦、急躁易怒、失眠梦、脉弦细数的失眠症;乌梅取其敛肺生津的功效,多药合用,同为佐药,协助调理失眠引起的各种症状。蜂蜜作为调和药,用于调和各药的药性,使本配方更加温和、有效;
本发明在总结验方的基础上,针对失眠的病因病机,按照中医辩证论治的组方原则,以补为主,补其五脏不足,达到扶正祛邪目的;以通为辅,通其气血滞瘀;以和为贵,调和诸药的药性;以清为佐,清脏腑热而安神。故补、通、和、清四法结合治疗多种原因引起的失眠,标本兼治,疗效显著。
(2)需要注意的是,本研究发现,当酸枣仁、人参、苦瓜的用量比例为1:(0.5-1.5):(1-2),其安神助眠效果明显,作为一个更优选地方案,酸枣仁、人参、苦瓜的用量比例为1:0.8:1.5,其安神助眠效果显著。另外,大量试验研究发现,去除苦瓜,其安神助眠效果也会大打折扣,因此酸枣仁、人参与苦瓜配合使用,具有协同增效之功;
(3)另外,因添加了龙眼肉超微粉、桔梗超微粉,两者固有的清香与微甜味,无需再刻意添加甜味剂或矫味剂,节省了生产成本与生产工序;
(4)本发明的酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅的使用超微粉技术更有利中药的充分吸收,进而缩短了药物使用疗程并减少用药剂量,提高了药物疗效,减少了药物在食品动物中的药物残留等带来的风险。
具体实施方式
下面,结合具体实施方式,对本发明做进一步描述:
在本发明中,若非特指,所有的份、百分比均为重量单位,所采用的设备和原料等均可从市场购得或是本领域常用的。下述实施例中的方法,如无特别说明,均为本领域的常规方法。
本发明提供一种安神助眠养颜复方制剂,由如下重量份数计组分制备而成:
优选地,该安神助眠养颜复方制剂由如下重量份数计组分制备而成:酸枣仁3.5-7.5份、龙眼肉4-9份、人参4-10.5份、茯苓3.5-4.5份、莲子3-5.5份、黄精1.5-2.5份、桔梗2.8-4.5份、苦瓜6-15份、乌梅1.2-2.8份、蜂蜜2.5-3.8份。
作为最优选地的方案,该安神助眠养颜复方制剂由如下重量份数计组分制备而成:酸枣仁6份、龙眼肉5.5份、人参4.8份、茯苓3.5份、莲子3.8份、黄精2份、桔梗3.2份、苦瓜9份、乌梅2.5份、蜂蜜2.9份。
酸枣仁:酸枣仁有补肝,宁心,敛汗,生津之功效,主要用于治疗虚烦不眠,惊悸多梦,体虚多汗和津伤口渴。酸枣仁是养心安神首选药品,在各类治疗失眠的中药制剂中,酸枣仁是最常用的组分。现代药理研究表明,酸枣仁具有镇静催眠、镇痛、抗惊厥、降血脂、抗血小板聚集、增强免疫功能、降压、抗缺氧、抗心肌缺血、抗心率失常、抗衰老、抗辐射等作用。
龙眼肉:性味性温,味甜。具有补益心脾,养血安神之功。用于气血不足、心悸怔忡、健忘失眠、血虚萎黄。现在药理研究表明,龙眼含有极其丰富的维生素C和钾,此外还含有大量的镁和铜,有补气益血之功效,对于治疗虚劳羸弱、失眠、健忘效果显著。
人参:味甘、性温、微苦,人参具有对多种疾病具有预防效果,对人体滋补脾益肺、生津止渴、安神益智、调荣养卫、大补元气、复脉固脱,在《神农本草经》中列为上品,是常用的滋补强壮药。人参能增强机体自身免疫功能。人参皂苷对正常动物的内皮系统的吞噬功能有刺激和促进作用,能使自身免疫增强,也是免疫调节剂。
茯苓:为常用的利水渗湿药,性昧:味甘、淡;性平;归心、肺、脾、肾经;茯苓有渗湿利水、益脾和胃、宁心安神等功效,内服可治疗脾虚、小便不利、水肿胀满、咳嗽痰多、泄泻、遗精、淋浊、惊悸、健忘等症。现代药理学研究茯苓具有利尿、免疫调节、保肝、抗肿瘤、抗氧化、抗炎、抗病毒等多种药理作用。
莲子:味涩性平,莲心味苦性寒,均有养生安神、补脾益肾之功效。作为一种重要的传统药物,早在汉朝的《神农本草经》便将莲子奉为上品,认为莲子具有镇静安神、补中益气、养心益肾的功效。现代研究莲子除含有多种维生素、微量元素外、还含有荷叶碱金丝草试等物质,对治疗神经衰弱、慢性胃炎、消化不良、高血压等有效。
黄精:味甘、性平,归脾、肺、肾经,具有健脾、补肾、润肺、生津等功能。《神仙芝草经》言其“宽中益气,使五脏调良,肌肉充盛,多年不老,颜色鲜明,发白更黑,齿落更生”,说明黄精有延年益寿、葆精养颜的作用。药理研究发现,黄精具有抗氧化、抗衰老、降血糖、降血脂、提高和改善记忆、抗肿瘤、调节免疫、抗病毒、抗炎等作用。
桔梗:桔梗为药食两用品种,具有宣肺,利咽,祛痰,排脓的功效。用于咳嗽痰多,胸闷不畅,咽痛,音哑,肺痈吐脓,疮疡脓成不溃。现代药理研究表明,桔梗具有祛痰作用、抗炎作用、免疫调节作用、抗肿瘤作用、保肝作用、心血管保护作用、治疗糖尿病作用、抗肥胖作用、镇痛作用。
苦瓜:性寒,味苦;入心、肝经。具有清热祛暑,明目解毒,利尿凉血之功,主治热病烦渴,中暑丹毒,目赤痈肿,痢疾,少尿等病症。现代药理研究发现,苦瓜可以通过清肝泻火来辅助治疗肝火上升型症状心悸而烦、急躁易怒、失眠梦、脉弦细数的失眠症。
乌梅:为药食同源的中药材,其味酸、性平无毒,归肝、脾、肺、大肠经、具有敛肺生津、涩肠安蛔之功。现代药理研究发现,其所含有的有机酸成分琥珀酸是乌梅具有镇静催眠及抗惊厥作用的主要成分。
蜂蜜:甘,平。归肺、脾、大肠经。具有补中,润燥,止痛,解毒之功。用于脘腹虚痛,肺燥干咳,肠燥便秘;外治疮疡不敛,水火烫伤。可补中益气、安五脏、和百药、解百毒,对神经衰弱的失眠有效。
经常失眠的人脸上的皮肤容易变得暗黄,黑眼圈也很重,整个人给人感觉好压抑。中医认为,导致失眠发生的主要原因是七情内伤,其病机总属营卫失和,阴阳失调为病之本。心是人体情志的发生之处和主宰者,心主神志,肝主情志,脾志为思,若情志不舒,思虑过度,不仅会影响肝之疏泄,出现肝郁气滞,化火扰神,而且进一步会耗伤心血,损伤脾运,最后发展还会出现心肾失交神志不宁,致使五脏俱虚。
本发明的安神助眠养颜复方制剂中,酸枣仁取其主治虚烦不眠,惊悸多梦之证,龙眼肉取其补益心脾,养血安神之功,人参取其滋补脾益肺、生津止渴、安神益智之功效,三药合用,作为君药,具有一起补血、宁心安神之功效。而茯苓取其益脾和胃、宁心安神的功效,莲子取其养生安神、补脾益肾的功效,黄精取其健脾、补肾、润肺的功效;三药合用,作为臣药,具有进一步辅助加强君药的宁心安神之功。而桔梗取其宣肺、排脓的功效,苦瓜取其清肝泻火的功效,来辅助治疗肝火上升型症状心悸而烦、急躁易怒、失眠梦、脉弦细数的失眠症;乌梅取其敛肺生津的功效,多药合用,同为佐药,协助调理失眠引起的各种症状。蜂蜜作为调和药,用于调和各药的药性,使本配方更加温和、有效。
本发明在总结验方的基础上,针对失眠的病因病机,按照中医辩证论治的组方原则,以补为主(酸枣仁、龙眼肉、人参),补其五脏不足,达到扶正祛邪目的;以通为辅(桔梗、黄精),通其气血滞瘀;以和为贵(蜂蜜),调和诸药的药性;以清为佐(苦瓜、莲子),清脏腑热而安神。故补、通、和、清四法结合治疗多种原因引起的失眠,标本兼治,疗效显著。
需要注意的是,本研究发现,当酸枣仁、人参、苦瓜的用量比例为1:(0.5-1.5):(1-2),其安神助眠效果明显,作为一个更优选地方案,酸枣仁、人参、苦瓜的用量比例为1:0.8:1.5,其安神助眠效果显著。另外,大量试验研究发现,去除苦瓜,其安神助眠效果也会大打折扣,因此酸枣仁、人参与苦瓜配合使用,具有协同增效之功。
另外,因添加了龙眼肉超微粉、桔梗超微粉,两者固有的清香与微甜味,无需再刻意添加甜味剂或矫味剂,节省了生产成本与生产工序。
作为本发明的优选方案,所述酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅的平均粒径均在300目以上。本发明的酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅的使用超微粉技术更有利中药的充分吸收,进而缩短了药物使用疗程并减少用药剂量,提高了药物疗效,减少了药物在食品动物中的药物残留等带来的风险。
本发明的安神助眠养颜复方制剂可按药剂学的常规工艺制备成任何一种内服制剂。
实施例1一种安神助眠养颜复方制剂
其由如下重量份数的组分制备而成:
酸枣仁6份、龙眼肉5.5份、人参4.8份、茯苓3.5份、莲子3.8份、黄精2份、桔梗3.2份、苦瓜9份、乌梅2.5份、蜂蜜2.9份。
制备方法,包括如下步骤:
(1)按配方量称取各个组分;
(2)乌梅去核留肉,将酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅烘干后,分别粉碎至超细粉,各药材粉末平均粒径均在300目以上,然后混合均匀,得到混合粉体;
(3)加入适量纯净水和蜂蜜的混合溶液,用搅拌桨缓慢匀速搅拌,搅拌40-45min后成桨料,向浆料内少量多次加入混合粉体,继续搅拌,直至混合均匀。
实施例2-8一种安神助眠养颜复方制剂
分别按下表1中的配比秤取原料,按照实施例1中的步骤进行制备,不同之处在于所添加的原料配比不同,制备产品,具体详见表1:
表1:实施例2-8原料配比表
对比实施例1一种安神助眠养颜复方制剂
其由如下重量份数的组分制备而成:
龙眼肉5.5份、茯苓3.5份、莲子3.8份、黄精2份、桔梗3.2份、苦瓜9份、乌梅2.5份、蜂蜜2.9份。
制备方法,同实施例1。
对比实施例2一种安神助眠养颜复方制剂
其由如下重量份数的组分制备而成:
酸枣仁6份、龙眼肉5.5份、人参4.8份、茯苓3.5份、莲子3.8份、黄精2份、桔梗3.2份、乌梅2.5份、蜂蜜2.9份。
制备方法,同实施例1。
下面,取实施例1-8以及对比实施例1-2制得的安神助眠养颜复方制剂,对安神助眠以及养颜效果进行检测,结果见表2。
将制备的实施例1-8以及对比实施例1-2制得的安神助眠养颜复方制剂分别发给100名失眠患者(100名失眠患者均有入睡困难,税后易醒,次晨感到头昏,嗜睡,精神不振,体倦乏力等症状,并且脸上色斑沉积、黯淡萎黄)使用,失眠患者服用安神助眠养颜复方制剂按照相同的方法服用,每天服用,连续服用一个月。每组实施例有10名失眠患者服用,失眠患者根据自己的感觉对睡眠状况以及面部容颜改善情况进行评分,评分采用10分制,1分为最差,5分适中,10分为最好,得分越高效果越好,睡眠情况改善包括入睡容易,睡后不易惊醒,睡醒后精神抖擞;面部容颜改善情况包括色斑淡化,肤色提亮;使用效果评价结果如表2。
表2实施例1-8及对比实施例1-2的测试结果
| 睡眠状况 | 色斑淡化程度 | |
| 对比实施例1 | 4.2 | 4.7 |
| 对比实施例2 | 4.8 | 5.4 |
| 实施例1 | 9.3 | 8.5 |
| 实施例2 | 6.2 | 6.1 |
| 实施例3 | 7.2 | 7.3 |
| 实施例4 | 8.1 | 7.6 |
| 实施例5 | 7.9 | 6.9 |
| 实施例6 | 7.6 | 7.9 |
| 实施例7 | 6.9 | 6.8 |
| 实施例8 | 6.1 | 6.0 |
由上表中数据可以看出,测试者服用本发明实施例1-8的安神助眠养颜复方制剂后,其睡眠状况及色斑淡化程度均有较好的改善,具体表现为入睡容易,睡后不易惊醒,睡醒后精神抖擞以及增加肌肤的光泽度,色斑淡化,且没有一例测试者出现过敏、皮肤不适等现象。尤其是,实施例1的配方比例,其改善睡眠情况及色斑淡化程度效果最佳,平均得分均在8.5以上。可见,本发明的配方其安神助眠、养颜效果较佳;主要通过扶正固本,调理自身身体的邪正虚实,并结合现代药理研究,通过合理调配各药的用量比例,尤其是酸枣仁、人参、苦瓜的比例,使该配方具有优异的安神助眠养颜效果。
值得注意的是,对比实施例1与实施例1的配方差异在于却少酸枣仁和人参,从效果来看,其改善睡眠情况及色斑淡化程度效果有所降低。对比实施例2与实施例1的配方差异在于去除苦瓜,其改善睡眠情况及色斑淡化程度效果大打折扣。进一步说明,本发明酸枣仁、人参、苦瓜的比例搭配,使该配方具有优异的安神助眠养颜效果。
对本领域的技术人员来说,可根据以上描述的技术方案以及构思,做出其它各种相应的改变以及形变,而所有的这些改变以及形变都应该属于本发明权利要求的保护范围之内。
Claims (9)
1.一种安神助眠养颜复方制剂,其特征在于,由如下重量份数计组分制备而成:
2.根据权利要求1所述的安神助眠养颜复方制剂,其特征在于,由如下重量份数计组分制备而成:
3.根据权利要求1所述的安神助眠养颜复方制剂,其特征在于,由如下重量份数计组分制备而成:
4.根据权利要求1-3任一项所述的安神助眠养颜复方制剂,其特征在于,所述酸枣仁、人参、苦瓜的用量比例为1:(0.5-1.5):(1-2)。
5.根据权利要求4所述的安神助眠养颜复方制剂,其特征在于,所述酸枣仁、人参、苦瓜的用量比例为1:0.8:1.5。
6.根据权利要求1-3任一项所述的安神助眠养颜复方制剂,其特征在于,所述酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅均粉碎成超细粉。
7.根据权利要求6所述的安神助眠养颜复方制剂,其特征在于,所述酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅的平均粒径均在300目以上。
8.一种如权利要求1-3任一项所述的安神助眠养颜复方制剂的制备方法,其特征在于,包括如下步骤:
(1)按配方量称取各个组分;
(2)乌梅去核留肉,将酸枣仁、龙眼肉、人参、茯苓、莲子、黄精、桔梗、苦瓜、乌梅烘干后,分别粉碎至超细粉,然后混合均匀,得到混合粉体;
(3)加入适量纯净水和蜂蜜的混合溶液,用搅拌桨缓慢匀速搅拌,搅拌40-45min后成桨料,向浆料内少量多次加入混合粉体,继续搅拌,直至混合均匀。
9.根据权利要求8所述的安神助眠养颜复方制剂的制备方法,其特征在于,所述步骤(2)中,各药材粉末平均粒径均在300目以上。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610758191.7A CN106361976A (zh) | 2016-08-29 | 2016-08-29 | 一种安神助眠养颜复方制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610758191.7A CN106361976A (zh) | 2016-08-29 | 2016-08-29 | 一种安神助眠养颜复方制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106361976A true CN106361976A (zh) | 2017-02-01 |
Family
ID=57900732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610758191.7A Withdrawn CN106361976A (zh) | 2016-08-29 | 2016-08-29 | 一种安神助眠养颜复方制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106361976A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106995772A (zh) * | 2017-05-18 | 2017-08-01 | 江苏洋河酒厂股份有限公司 | 一种增强免疫力的保健酒 |
| CN109463589A (zh) * | 2018-12-28 | 2019-03-15 | 凯瑞欧(天津)生物技术有限公司 | 一种改善睡眠质量的酸枣仁配方饮料及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1528402A (zh) * | 2003-10-13 | 2004-09-15 | 张华贵 | 一种滋补安眠液 |
| CN101107995A (zh) * | 2007-08-09 | 2008-01-23 | 于洪文 | 一种中药保健袋泡饮品 |
-
2016
- 2016-08-29 CN CN201610758191.7A patent/CN106361976A/zh not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1528402A (zh) * | 2003-10-13 | 2004-09-15 | 张华贵 | 一种滋补安眠液 |
| CN101107995A (zh) * | 2007-08-09 | 2008-01-23 | 于洪文 | 一种中药保健袋泡饮品 |
Non-Patent Citations (1)
| Title |
|---|
| 余家会等主编: "《纳米生物医药》", 31 December 2011, 华东理工大学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106995772A (zh) * | 2017-05-18 | 2017-08-01 | 江苏洋河酒厂股份有限公司 | 一种增强免疫力的保健酒 |
| CN109463589A (zh) * | 2018-12-28 | 2019-03-15 | 凯瑞欧(天津)生物技术有限公司 | 一种改善睡眠质量的酸枣仁配方饮料及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283999B (zh) | 一种治疗失眠的中药制剂 | |
| CN103877263B (zh) | 一种红参、玛咖、绿茶提取物(茶氨酸)等复合中药抗疲劳养生制剂 | |
| CN102078520A (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
| CN103830555A (zh) | 一种药酒及其制备方法和用途 | |
| CN101700336B (zh) | 一种治疗颅脑外伤后遗性头痛的中药制剂及其制备方法 | |
| CN106214964A (zh) | 安神的中药制剂 | |
| CN108355088A (zh) | 一种改善睡眠质量的酸枣仁药酒及其制备方法 | |
| CN104274754A (zh) | 一种治疗小儿遗尿的中药组合物及其制备方法 | |
| CN106361976A (zh) | 一种安神助眠养颜复方制剂及其制备方法 | |
| CN105796845A (zh) | 药物组合物在制备治疗女性更年期综合征药物中的用途 | |
| CN105796981A (zh) | 用于改善亚健康状态的中药口服液及其制备方法 | |
| CN102091228B (zh) | 一种治疗失眠的药物及其制备方法 | |
| CN101897941A (zh) | 一种抗衰老的中药配方及其制备方法 | |
| CN104524479B (zh) | 一种治疗经前期综合征的中药组合物及其制备方法 | |
| CN103725587A (zh) | 黄精山楂醋及其生产方法 | |
| CN104324134B (zh) | 一种改善微循环的中药组合物及其制备方法 | |
| CN108524861A (zh) | 一种治疗失眠的中药膏及其制备方法 | |
| CN103223137B (zh) | 一种降血糖的中药制剂 | |
| CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
| CN114698841A (zh) | 一种促进血液循环改善亚健康的本草提取物 | |
| CN105343675A (zh) | 一种治疗肥胖症的中药制剂及其制备方法 | |
| CN105343808A (zh) | 一种具有减肥效果的中药组合物及其制备方法 | |
| CN105362629A (zh) | 一种含有杜仲的治疗女性更年期综合症的药物组合物及其制备方法 | |
| CN104435685A (zh) | 一种治疗干眼症的药物及其制备方法 | |
| CN112439038A (zh) | 一种快速改善睡眠的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170201 |
|
| WW01 | Invention patent application withdrawn after publication |